A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377 · Completed
Last updated 2026-05-28This clinical trial is testing different doses of the medication BI 456906 in adults with overweight or obesity to see how it affects weight loss over 46 weeks.
What this study is testing ClinicalTrials.gov NCT04667377 ↗
Description as written by the study sponsor.
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine. Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.
Treatments tested
- BI 456906 also known as Survodutide Drug
BI 456906
- Placebo Drug
Placebo
| Main thing measured | Percentage Change in Body Weight From Baseline to Week 46 |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Conditions studied | Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04667377 ↗